

Cetuximab, bevacizumab and panitumumab monotherapy for the treatment of metastatic colorectal cancer that has progressed after first line chemotherapy (review of technology appraisal 150 and part-review of technology appraisal 118)

Roche Assessment Report Comments

- 1. Page 24:** *'There is an absence of RCT evidence of bevacizumab combined with non-oxaliplatin chemotherapy'* should be amended. This statement is not factually correct. It should be amended to reflect the fact that there is evidence demonstrating the efficacy of bevacizumab in combination with non-oxaliplatin based chemotherapy in previously untreated mCRC but not in subsequent lines of treatment. This comment similarly applies to page 207.
- 2. Page 36:** Here it is noted that bevacizumab is *'contraindicated in patients who ... have untreated central nervous system metastases'*. This is not factually correct. Whilst this was previously a contraindication for bevacizumab this is no longer the case and section 4.3 of the bevacizumab's SPC ('contraindications') contains nothing on CNS metastases. This comment should therefore be removed.